West Pharmaceutical Services/$WST
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About West Pharmaceutical Services
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Ticker
$WST
Sector
Primary listing
NYSE
Employees
10,600
Headquarters
Website
WST Metrics
BasicAdvanced
$19B
38.65
$6.68
1.05
$0.84
0.33%
Price and volume
Market cap
$19B
Beta
1.05
52-week high
$348.90
52-week low
$187.43
Average daily volume
553K
Dividend rate
$0.84
Financial strength
Current ratio
2.78
Quick ratio
1.852
Long term debt to equity
9.764
Total debt to equity
10.522
Dividend payout ratio (TTM)
12.32%
Interest coverage (TTM)
1,568.00%
Profitability
EBITDA (TTM)
795.6
Gross margin (TTM)
35.27%
Net profit margin (TTM)
16.48%
Operating margin (TTM)
21.39%
Effective tax rate (TTM)
20.21%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
10.64%
Return on equity (TTM)
17.72%
Valuation
Price to earnings (TTM)
38.648
Price to revenue (TTM)
6.327
Price to book
6.34
Price to tangible book (TTM)
6.61
Price to free cash flow (TTM)
54.449
Free cash flow yield (TTM)
1.84%
Free cash flow per share (TTM)
4.745
Dividend yield (TTM)
0.33%
Forward dividend yield
0.33%
Growth
Revenue change (TTM)
2.90%
Earnings per share change (TTM)
-5.00%
3-year revenue growth (CAGR)
0.36%
10-year revenue growth (CAGR)
7.77%
3-year earnings per share growth (CAGR)
-9.33%
10-year earnings per share growth (CAGR)
14.74%
3-year dividend per share growth (CAGR)
5.34%
10-year dividend per share growth (CAGR)
6.80%
What the Analysts think about WST
Analyst ratings (Buy, Hold, Sell) for West Pharmaceutical Services stock.
Bulls say / Bears say
West raised its annual profit and sales forecasts for 2025, citing benefits from a weaker U.S. dollar and robust demand for medical device components—projecting adjusted EPS of $6.15–$6.35 and sales of $2.95–$2.98 billion—underscoring management’s confidence in continued growth (Reuters)
Shares surged over 24% on July 24 after West reported Q2 2025 adjusted EPS of $1.84 and revenue of $766.5 million, both well above consensus, reflecting strong operational execution and positive investor sentiment (Barron's)
As major pharmaceutical companies accelerate U.S. manufacturing expansions to mitigate tariff risks, West’s extensive domestic network of 25 facilities positions it to capture increased demand for locally sourced drug-packaging and delivery components (Reuters)
West continues to face significant margin risk from trade policies, still expecting a $20 million to $25 million headwind from recently implemented tariffs for the remainder of 2025, which could erode profitability if trade tensions persist (Reuters)
The decision to exit next-generation continuous glucose monitoring contracts has resulted in the loss of two major long-standing customers and triggered class-action litigation, highlighting revenue and reputational risks associated with strategic customer shifts (Bloomberg Law)
Competition is intensifying as major peers like Roche commit over $700 million to a new North Carolina manufacturing facility, potentially putting pressure on West’s market share and pricing power in key packaging and delivery segments (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.
WST Financial Performance
Revenues and expenses
WST Earnings Performance
Company profitability
WST News
AllArticlesVideos
West Pharma raises annual profit forecast on strong demand for its drug components
Reuters2 months ago
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of West Pharmaceuticals
Business Wire2 months ago
Deadline Soon: West Pharmaceutical Services, Inc. (WST) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
Business Wire3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Nov12
West Pharmaceutical Services
DividendEx-dividend
Nov19
West Pharmaceutical Services
DividendPayment
$0.22Per share
FAQs
What’s the current market cap for West Pharmaceutical Services stock?
West Pharmaceutical Services (WST) has a market cap of $19B as of September 17, 2025.
What is the P/E ratio for West Pharmaceutical Services stock?
The price to earnings (P/E) ratio for West Pharmaceutical Services (WST) stock is 38.65 as of September 17, 2025.
Does West Pharmaceutical Services stock pay dividends?
Yes, the West Pharmaceutical Services (WST) stock pays dividends to shareholders. As of September 17, 2025, the dividend rate is $0.84 and the yield is 0.33%. West Pharmaceutical Services has a payout ratio of 12.32% on a trailing twelve-month basis.
When is the next West Pharmaceutical Services dividend payment date?
The next West Pharmaceutical Services (WST) dividend payment is scheduled for November 19, 2025.
What is the beta indicator for West Pharmaceutical Services?
West Pharmaceutical Services (WST) has a beta rating of 1.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.